Quarterly 13F snapshot: US-listed longs only, no performance figures — 13F data cannot support them.
Reported portfolio value by quarter (34 quarters reported)
$138M in Q2 2013 → $50.7M now. Hover for any quarter.
As reported for the quarter ended September 30, 2021. Activity is the change in share count since the prior quarter's filing.
| Holding | % of portfolio | Activity | Shares | Value |
|---|---|---|---|---|
| Gilead Sciences Inc | 8.3% | Trimmed 20% | 60,000 | $4.19M |
| GP Glaxosmithkline PLC | 7.5% | Unchanged | 100,000 | $3.82M |
| Pfizer Inc | 6.4% | Trimmed 25% | 75,000 | $3.23M |
| Alkermes PLC Put | 6.1% | New | 100,000 | $3.08M |
| Alkermes PLC | 6.1% | Trimmed 33% | 100,000 | $3.08M |
| AP Amryt Pharma PLC | 6.0% | Added 25% | 250,000 | $3.02M |
| Merck & Co Inc | 5.9% | Unchanged | 40,000 | $3M |
| Astrazeneca PLC | 5.9% | Unchanged | 50,000 | $3M |
| Bristol-myers Squibb Co | 5.8% | Unchanged | 50,000 | $2.96M |
| PT Proshares Tr Call | 5.2% | Added 200% | 150,000 | $2.63M |
| Ironwood Pharmaceuticals Inc | 5.2% | Unchanged | 200,000 | $2.61M |
| CO Clovis Oncology Inc | 4.4% | Unchanged | 500,000 | $2.23M |
| Pfizer Inc Put | 4.2% | New | 50,000 | $2.15M |
| TT Tyme Technologies Inc | 4.1% | Added 33% | 2,000,000 | $2.06M |
| AP Antares Pharma Inc | 3.6% | Unchanged | 500,000 | $1.82M |
| PT Proshares Tr Call | 3.4% | Added 100% | 200,000 | $1.73M |
| PT Proshares Tr Ii Call | 2.4% | New | 50,000 | $1.23M |
| Amarin Corp PLC Call | 2.0% | Unchanged | 200,000 | $1.02M |
| Vertex Pharmaceuticals Inc | 1.8% | New | 5,000 | $907K |
| GH Greenlane Hldgs Inc | 1.6% | Unchanged | 350,000 | $830K |
| VT Vyne Therapeutics Inc | 1.1% | Trimmed 11% | 400,000 | $556K |
| AP Adamas Pharmaceuticals Inc | 1.0% | Unchanged | 100,000 | $491K |
| GC Gamida Cell Ltd | 0.8% | Added 33% | 100,000 | $392K |
| Durect Corp | 0.6% | New | 250,000 | $320K |
| PT Proshares Tr Ii Call | 0.6% | Trimmed 50% | 12,500 | $285K |
What changed each quarter, from the filings' own share counts. Largest moves first; most recent 8 quarters.
quarter ended September 30, 2021 · filed November 15, 2021
| Company | Action | Shares changed | Value of change | % of portfolio |
|---|---|---|---|---|
| Alkermes PLC | New | +100,000 | +$3.08M | 6.1% |
| Collegium Pharmaceutical Inc | Exited | −100,000 | −$2.36M | — |
| Pfizer Inc | New | +50,000 | +$2.15M | 4.2% |
| PT Proshares Tr | Added | +100,000 | +$1.75M | 5.2% |
| Mimedx Group Inc | Exited | −125,000 | −$1.56M | — |
| Alkermes PLC | Trimmed | −50,000 | −$1.54M | 6.1% |
| PT Proshares Tr Ii | New | +50,000 | +$1.23M | 2.4% |
| Pfizer Inc | Trimmed | −25,000 | −$1.08M | 6.4% |
| Gilead Sciences Inc | Trimmed | −15,000 | −$1.05M | 8.3% |
| Vertex Pharmaceuticals Inc | New | +5,000 | +$907K | 1.8% |
Showing the 10 largest of 18 changes.
quarter ended June 30, 2021 · filed August 16, 2021
| Company | Action | Shares changed | Value of change | % of portfolio |
|---|---|---|---|---|
| Bristol-myers Squibb Co | Added | +25,000 | +$1.67M | 6.7% |
| Mimedx Group Inc | New | +125,000 | +$1.56M | 3.1% |
| Merck & Co Inc | Added | +20,000 | +$1.56M | 6.2% |
| Astrazeneca PLC | Added | +25,000 | +$1.5M | 6.0% |
| Aurinia Pharmaceuticals Inc | Exited | −100,000 | −$1.3M | — |
| Alkermes PLC | Added | +50,000 | +$1.23M | 7.3% |
| PT Proshares Tr Ii | Exited | −100,000 | −$935K | — |
| PT Proshares Tr | New | +100,000 | +$914K | 1.8% |
| PT Proshares Tr | Trimmed | −50,000 | −$911K | 1.8% |
| PT Proshares Tr Ii | New | +25,000 | +$602K | 1.2% |
Showing the 10 largest of 16 changes.
quarter ended March 31, 2021 · filed May 17, 2021
| Company | Action | Shares changed | Value of change | % of portfolio |
|---|---|---|---|---|
| Abbvie Inc | Exited | −35,000 | −$3.75M | — |
| Pfizer Inc | New | +100,000 | +$3.62M | 8.1% |
| VT Vyne Therapeutics Inc | Exited | −2,000,000 | −$3.16M | — |
| VT Vyne Therapeutics Inc | New | +400,000 | +$2.74M | 6.1% |
| Collegium Pharmaceutical Inc | New | +100,000 | +$2.37M | 5.3% |
| PT Proshares Tr | New | +100,000 | +$2.37M | 5.3% |
| Ironwood Pharmaceuticals Inc | New | +200,000 | +$2.24M | 5.0% |
| AP Amryt Pharma PLC | New | +155,555 | +$2.17M | 4.8% |
| Alkermes PLC | New | +100,000 | +$1.87M | 4.2% |
| Mckesson Corp | Exited | −10,000 | −$1.74M | — |
Showing the 10 largest of 23 changes.
quarter ended December 31, 2020 · filed February 16, 2021
| Company | Action | Shares changed | Value of change | % of portfolio |
|---|---|---|---|---|
| Jazz Pharmaceuticals PLC | Trimmed | −15,000 | −$2.48M | 5.6% |
| PT Proshares Tr | Exited | −250,000 | −$2.18M | — |
| Amarin Corp PLC | Added | +200,000 | +$978K | 4.9% |
| PT Proshares Tr | Exited | −100,000 | −$870K | — |
| GC Gamida Cell Ltd | New | +50,000 | +$420K | 1.4% |
| PT Proshares Tr Ii | Added | +25,000 | +$344K | 2.3% |
| VT Vyne Therapeutics Inc | Added | +200,000 | +$316K | 10.6% |
quarter ended September 30, 2020 · filed November 16, 2020
| Company | Action | Shares changed | Value of change | % of portfolio |
|---|---|---|---|---|
| VT Vyne Therapeutics Inc | New | +1,800,000 | +$2.99M | 9.8% |
| MT Menlo Therapeutics Inc | Exited | −1,700,000 | −$2.94M | — |
| Walgreens Boots Alliance Inc | Exited | −50,000 | −$2.12M | — |
| Cvs Health Corp | Exited | −25,000 | −$1.62M | — |
| A Amerisourcebergen Corp | Exited | −15,000 | −$1.51M | — |
| Cardinal Health Inc | Trimmed | −25,000 | −$1.17M | 3.9% |
| Abbvie Inc | Added | +10,000 | +$876K | 10.1% |
| PT Proshares Tr | Trimmed | −100,000 | −$870K | 2.9% |
| Jazz Pharmaceuticals PLC | Added | +6,000 | +$856K | 11.7% |
| Viking Therapeutics Inc | Exited | −100,000 | −$721K | — |
Showing the 10 largest of 15 changes.
quarter ended June 30, 2020 · filed August 14, 2020
| Company | Action | Shares changed | Value of change | % of portfolio |
|---|---|---|---|---|
| Gilead Sciences Inc | Exited | −50,000 | −$3.74M | — |
| Astrazeneca PLC | Exited | −75,000 | −$3.35M | — |
| LA Laboratory Corp Amer Hldgs | Exited | −25,000 | −$3.16M | — |
| DS Direxion Shs ETF Tr | Exited | −120,000 | −$3.13M | — |
| AP Alexion Pharmaceuticals Inc | Exited | −30,000 | −$2.69M | — |
| Abbvie Inc | Trimmed | −25,000 | −$2.46M | 6.3% |
| Mckesson Corp | Trimmed | −15,000 | −$2.3M | 3.9% |
| A Amerisourcebergen Corp | Trimmed | −15,000 | −$1.51M | 3.9% |
| PT Proshares Tr | Added | +125,000 | +$1.48M | 6.0% |
| MT Menlo Therapeutics Inc | Added | +850,000 | +$1.47M | 7.5% |
Showing the 10 largest of 18 changes.
quarter ended March 31, 2020 · filed May 15, 2020
| Company | Action | Shares changed | Value of change | % of portfolio |
|---|---|---|---|---|
| Gilead Sciences Inc | New | +50,000 | +$3.74M | 6.3% |
| PT Proshares Tr | New | +150,000 | +$3.62M | 6.1% |
| Astrazeneca PLC | New | +75,000 | +$3.35M | 5.6% |
| LA Laboratory Corp Amer Hldgs | New | +25,000 | +$3.16M | 5.3% |
| DS Direxion Shs ETF Tr | New | +120,000 | +$3.13M | 5.3% |
| Jazz Pharmaceuticals PLC | New | +30,000 | +$2.99M | 5.0% |
| AP Alexion Pharmaceuticals Inc | New | +30,000 | +$2.69M | 4.5% |
| MT Menlo Therapeutics Inc | New | +850,000 | +$2.28M | 3.8% |
| Mckesson Corp | Added | +15,000 | +$2.03M | 5.7% |
| Viking Therapeutics Inc | Exited | −250,000 | −$2.01M | — |
Showing the 10 largest of 24 changes.
quarter ended December 31, 2019 · filed February 14, 2020
| Company | Action | Shares changed | Value of change | % of portfolio |
|---|---|---|---|---|
| SS SPDR S&P 500 ETF Tr | Exited | −50,000 | −$14.8M | — |
| PT Proshares Tr Ii | Exited | −200,000 | −$3.9M | — |
| Gilead Sciences Inc | Exited | −50,000 | −$3.17M | — |
| Walgreens Boots Alliance Inc | Exited | −50,000 | −$2.77M | — |
| CO Clovis Oncology Inc | New | +100,000 | +$1.04M | 3.1% |
| CO Clovis Oncology Inc | Trimmed | −100,000 | −$1.04M | 4.6% |
| AP Adamas Pharmaceuticals Inc | Exited | −200,000 | −$1.02M | — |
| NT Novelion Therapeutics Inc | Exited | −1,400,000 | −$1.02M | — |
| AP Adamas Pharmaceuticals Inc | New | +200,000 | +$758K | 2.2% |
| AP Antares Pharma Inc | Exited | −200,000 | −$669K | — |
Showing the 10 largest of 14 changes.
Loading...
